ReviewCurrent psychiatry reports2012
Is there anything really novel on the antidepressant horizon?
Review in Current psychiatry reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 70 citations in OpenAlex.
- The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder.Journal of psychopharmacology (Oxford, England) · 2022Trial
- A pilot study on high amplitude low frequency-music impulse stimulation as an add-on treatment for depression.Brain and behavior · 2019Trial
- A Novel Strategy to Identify Placebo Responders: Prediction Index of Clinical and Biological Markers in the EMBARC Trial.Psychotherapy and psychosomatics · 2018Trial
- A randomized controlled trial of intranasal ketamine in major depressive disorder.Biological psychiatry · 2014Trial
- Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.The American journal of psychiatry · 2013Trial
- Advancing Antidepressive Agents: Drug Discovery and Polymer-Based Drug Delivery Systems for Improved Treatment Outcome.Biomedicines · 2025Review
- Protein associations and protein-metabolite interactions with depressive symptoms and the p-factor.Translational psychiatry · 2025Article
- Depression proteomic profiling in adolescents with transcriptome analyses in independent cohorts.Frontiers in psychiatry · 2024Article
- Potential antidepressant effects of Traditional Chinese botanical drug formula Chaihu-Shugan-San and its active ingredients.Frontiers in pharmacology · 2024Review
- Stress-related reduction of hippocampal subfield volumes in major depressive disorder: A 7-Tesla study.Frontiers in psychiatry · 2023Article
- Annual costs among patients with major depressive disorder and the impact of key clinical events.Journal of managed care & specialty pharmacy · 2022Article
- Branched-chain amino acids linked to depression in young adults.Frontiers in neuroscience · 2022Article
- Animal models of PTSD: a challenge to be met.Molecular psychiatry · 2019Review
- Review
- Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation.International journal of molecular sciences · 2018Review
- Engaging homeostatic plasticity to treat depression.Molecular psychiatry · 2018Review
- Efficacy of different doses of ketamine as a bolus in major depressive disorder.Caspian journal of internal medicine · 2018Article
- Pushing the threshold: How NMDAR antagonists induce homeostasis through protein synthesis to remedy depression.Brain research · 2016Review
- Timosaponin derivative YY-23 acts as a non-competitive NMDA receptor antagonist and exerts a rapid antidepressant-like effect in mice.Acta pharmacologica Sinica · 2016Article
- Evidence for alterations of the glial syncytial function in major depressive disorder.Journal of psychiatric research · 2016Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Major depression represents one of the most disabling illnesses worldwide and current treatments are only partially effective. All antidepressant agents modulate the monoamine system, which likely accounts for the similar efficacy profile of available treatments. Herein we summarize the current state of depression therapeutics and assess the antidepressant development pipeline. Antidepressant response rates in controlled trials are estimated at ~54 % and real-world effectiveness data suggests a somewhat lower rate. Response rates are lower still in patients who have not responded to previous treatment attempts and meaningful advancements will likely come only from identification of mechanistically novel agents. Monoaminergic agents largely dominate the antidepressant development pipeline, however the glutamate neurotransmitter system represents a bright spot on the antidepressant horizon. We review in detail findings regarding the antidepressant effects of the glutamate N-methyl-d-aspartate receptor antagonist ketamine in order to highlight the promise of novel agents as future treatments for major depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.